ANCN Anchiano Therapeutics Ltd

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Cohen Neil Harris	2. Issuer Name and Ticker or Trading Symbol Chemomab Therapeutics Ltd. [ CMMB ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                    _____ 10% Owner _____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle) C/O CHEMOMAB THERAPEUTICS LTD.,, 1 KENDALL SQ, BLDG 1400E, STE 14-105	3. Date of Earliest Transaction (MM/DD/YYYY) 3/16/2023
(Street) CAMBRIDGE, MA 02139	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person
(City)        (State)        (Zip)	Rule 10b5-1(c) Transaction Indication ☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
American Depositary Shares (2)								10000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase American Depositary Shares	$1.62	3/16/2023		A		6875		(3)	3/21/2033	American Depositary Shares (1)	6875	$0	6875	D
Option to Purchase American Depositary Shares (2)	$3.53	3/7/2022		A		6820		(4)	3/7/2032	American Depositary Shares (1)	6820	$0	6820	D
Option to Purchase American Depositary Shares (2)	$27.26	4/19/2021		A		11884		(5)	4/19/2031	American Depositary Shares (1)	11884	$0	11884	D
Option to Purchase American Depositary Shares (2)	$13.17	3/16/2021		A		688		(6)	7/15/2030	American Depositary Shares (1)	688	$0	688	D

Explanation of Responses:
(1)	Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.
(2)	No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
(3)	These options were granted as per the annual grant of options to directors. Those options vest and become exercisable in their entirety on March 16, 2024, subject to the Reporting Person's continued service.
(4)	These options vested and became exercisable in their entirety on March 16, 2023. These options were granted as per the annual grant of options to directors
(5)	These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service.
(6)	These options vest and become exercisable as follows: 1/3 vested on July 16, 2021, and the remaining options vest on a quarterly basis for the following eight quarters, subject to the Reporting Person's continued service.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Cohen Neil Harris C/O CHEMOMAB THERAPEUTICS LTD., 1 KENDALL SQ, BLDG 1400E, STE 14-105 CAMBRIDGE, MA 02139	X

Signatures
/s/ Neil Cohen		3/23/2023
**Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.